Meda AB

Type: Company
Name: Meda AB
Nationality: Sweden
Web Address: http://www.meda.se/
Fact Sheet: Fact Sheet for Meda AB
First reported Jul 31 2014 - Updated 17 hours ago - 2 reports

Meda Buys Rottapharm for $3.1B

Meda said today it will buy Rottapharm Madaus for SEK 21.2 billion (about $3.1 billion) from Italy’s Rovati family, in a deal the buyer said reflected its desire to grow into a leading specialty pharma through acquisitions—namely by combining the seller’s ... [Published Genetic Engineering News - 17 hours ago]
First reported Jul 31 2014 - Updated 19 hours ago - 5 reports

Derivatives: Anticipated adjustment due to rights issue in Meda (58/14)

The following information is based on a press release from Meda AB (Meda) published on July 31, 2014 and may be subject to change. The board of Meda plans a rights issue for existing shareholders, which is expected to be proposed to an Extraordinary General ... [Published Street Sweeper - 19 hours ago]
Entities: Meda AB
First reported 21 hours ago - Updated 21 hours ago - 1 reports

Why Pharma Companies Are Rushing To Relocate Overseas

Pharma companies are relocating overseas primarily because they want to benefit from tax inversion, which leads to lower tax ratesClick Ticker to See live coverageSeveral US-based companies are racing to acquire foreign rivals to grab tax inversion opportunities. ... [Published Bidness Etc - 21 hours ago]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

BioDelivery Sciences Appoints Charles J. Bramlage -2-

undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.BDSI(R) and BEMA(R) are registered trademarks of BioDelivery Sciences ... [Published Scottrade - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 2 reports

Shire Agrees to AbbVie $55B Takeover Offer

07/18/14 - 10:37 AM EDTLONDON ( The Deal ) -- AbbVie ( ABBV ) forged a 32 billion pounds ($54.7 billion) takeover deal for Shire ( SHPG ) Friday, having agreed to a $500 million-plus, one-way breakup fee amid concerns a potential U.S. clampdown on companies ... [Published TheStreet.com - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 2 reports

Sun Pharma buys US drug maker

After its $3.2-billion acquisition of Ranbaxy, Sun Pharmaceuticals has announced a buyout of US-based Pharmalucence Inc.The deal is expected to help Sun enter into the new area of radio pharmaceuticals and strengthen its presence in the injectable business ... [Published Business Standard India - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 4 reports

AbbVie bids $54B for Shire in latest tax-inversion deal

Drugmakers AbbVie and Shire have entered detailed talks about a possible merger after AbbVie raised its bid to $54 billion US.Shire, based on the British island of Jersey, said it is interested in accepting the offer after AbbVie proposed a cash-stock ... [Published CBC - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

European Stocks Rise As Portuguese Bank Hires New CEO

European stocks rebounded on Monday after steep losses last week, helped by hopes that Portugal can avert another banking crisis.Vítor Bento was named new chief executive at Banco Espírito Santo SA, whose shares dropped another 8 percent. Still, the move ... [Published RTTNews.com - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

European Stocks Rise After Weekly Decline; Shire Climbs on Bid

July 14 (Bloomberg) -- European stocks climbed, after the Stoxx Europe 600 Index posted its biggest weekly drop since March, as Shire Plc gained. U.S. stock futures and Asian shares also advanced.Shire added 2.7 percent after saying it is willing to recommend ... [Published Washington Post - Jul 14 2014]
First reported Jul 11 2014 - Updated Jul 12 2014 - 3 reports

Mylan set to buy Abbott drug assets

19:48 ET | About: Mylan Inc (MYL)Reuters reports that generic drug firm Mylan (MYL -1%) is in advanced negotiations with Abbott Laboratories (ABT +0.1%) to purchase a multibillion dollar portfolio of its established off-patent Europe-based drugs. The ... [Published Seeking Alpha - Jul 12 2014]
First reported May 07 2014 - Updated May 08 2014 - 1 reports

Meda AB (publ) AGM bulletin

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: At the annual general meeting (AGM) on May 7, 2014, of Meda AB (STO:MEDAA) (publ), corporate ID 556427-2812, Box 906, SE-170 09 Solna, Sweden, declared a dividend of 2,50 SEK per share. The AGM adopted ... [Published Business Wire Health News - May 07 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 2 reports

MEDA: Nomination Committee’s Proposal for Composition of the Board

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda AB (STO:MEDAA): The Nomination Committee of Meda AB proposes the election of Guido Oelkers and Martin Svalstedt as new board members and proposes the appointment of Martin Svalstedt as Board Chairman. ... [Published Business Wire Health News - Mar 28 2014]

Quotes

...Luca Rovati, CEO of Rottapharm. "We are now ready to take the next step. We are very pleased to have reached this agreement with Meda and are confident that this will create significant value in the long-term for all our stakeholders. Through Meda's expertise and resources, we are also confident that our medications will continue to serve patients and doctors alike going forward. Also, I very much look forward to contributing to the future success of the combined business as second largest shareholder in Meda." Enhanced scale, reach and profitability
...patient population with substantial unmet need, there's little pricing sensitivity and there is little business case for generic erosion," he said. "If anything, this deal validates the rare disease business model. Depending on how you do the math they could be the No. 2 or No. 3."
Ranjit Kapadia of Centrum Broking said, "The new facility of Pharmalucence, which is awaiting FDA approval will give a boost for Sun’s presence in injectables." Pharmalucence’s 70,000 sq ft facility is claimed to be region's first contract manufacturing facility
"You can't go for small companies," he said. "Glaxo is too big, Astra has had an approach from Pfizer and Shire has now gone."

More Content

All (61) | News (36) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (2) | Press Releases (8)
sort by: Date | Relevance
Meda Buys Rottapharm for $3.1B [Published Genetic Engineering News - 17 hours ago]
Derivatives: Anticipated adjustment due to righ... [Published Street Sweeper - 19 hours ago]
Why Pharma Companies Are Rushing To Relocate Ov... [Published Bidness Etc - 21 hours ago]
Meda to buy drugs maker Rottapharm for $3.08 bi... [Published Morningstar.com - 22 hours ago]
The Wall Street Journal: Meda to buy drugs make... [Published Austin American Statesman - 22 hours ago]
Meda buys Italian pharma firm [Published Seeking Alpha - 22 hours ago]
Meda To Buy Rottapharm For SEK 21.2 Bln On Cash... [Published RTTNews.com - Jul 31 2014]
Meda to acquire Rottapharm, creating a European... [Published Noodls - Jul 31 2014]
BioDelivery Sciences Appoints Charles J. Bramla... [Published Scottrade - Jul 22 2014]
Shire Agrees to AbbVie $55B Takeover Offer [Published TheStreet.com - Jul 18 2014]
Shire Agrees to AbbVie $55B Takeover Offer [Published The Street Latest - Jul 18 2014]
Sun Pharma buys US drug maker [Published Business Standard India - Jul 16 2014]
Sun Pharma buys US-based Pharmalucence to boost... [Published Business Standard India - Jul 16 2014]
AbbVie bids $54B for Shire in latest tax-invers... [Published CBC - Jul 14 2014]
European Stocks Rise As Portuguese Bank Hires N... [Published RTTNews.com - Jul 14 2014]
UPDATE 4-Shire ready to bow to AbbVie's increas... [Published London South East - Jul 14 2014]
Another US pharma firm in UK merger to avoid taxes [Published New York Post - Jul 14 2014]
US stocks rise with Portuguese bonds as treasur... [Published Livemint.com - Jul 14 2014]
European Stocks Extend Gains For Second Day [Published HispanicBusiness.com - Jul 14 2014]
Shire ready to bow to AbbVie's increased $53 bi... [Published Reuters - Jul 14 2014]
European Stocks Rise After Weekly Decline; Shir... [Published Washington Post - Jul 14 2014]
Mylan Chasing Abbott’s Multi-Billion Dollar Off... [Published Bidness Etc - Jul 12 2014]
Mylan set to buy Abbott drug assets [Published Seeking Alpha - Jul 12 2014]
EXCLUSIVE : Mylan near multibillion-dollar deal... [Published 4 Traders - Jul 12 2014]
Mylan near multibillion-dollar deal for Abbott ... [Published Sharenet - Jul 11 2014]
Why Mylan Should Buy Alkermes [Published Motley Fool - Jul 08 2014]
BioDelivery Sciences Announces Completion of Pa... [Published ADVFN India - Jun 26 2014]
Mission Pharmacal starts promotion of Elestrin ... [Published PharmaBiz - May 31 2014]
Mission Pharmacal Begins Exclusive Promotion of... [Published PR Newswire: General Business - May 29 2014]
Listing of bond loan(s) issued by Meda AB (publ... [Published GlobeNewswire: Acquisitions News - May 21 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Mission Pharmacal Begins Exclusive Promotion of... [Published PR Newswire: General Business - May 29 2014]
SAN ANTONIO, May 29, 2014 /PRNewswire/ -- Mission Pharmacal Company has begun exclusive promotion of Elestrin® (estradiol gel) 0.06% in the United States through an agreement with Meda AB. Elestrin is a prescription medicine approved by the Food and ...
Meda AB (publ) AGM bulletin [Published Business Wire Health News - May 07 2014]
GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: At the annual general meeting (AGM) on May 7, 2014, of Meda AB (STO:MEDAA) (publ), corporate ID 556427-2812, Box 906, SE-170 09 Solna, Sweden, declared a dividend of 2,50 SEK per share. The AGM adopted ...
MEDA: Interim Report, January-March 2014 [Published Business Wire Health News - May 07 2014]
GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda AB (STO:MEDAA): January-March 2014·The Group’s net sales reached SEK 3,365 million (3,199), corresponding to organic growth[1] of 3% compared to the previous year.·EBITDA was SEK 1,010 million (923), ...
ASTEPRO (Azelastine Hydrochloride) Spray, Meter... [Published DailyMed Drug Label Updates for the last seven ... - May 01 2014]
Updated Date: Apr 28, 2014 EST ...
Statement by the Board of Directors of Meda in ... [Published Business Wire Health News - Apr 28 2014]
GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: This statement is made by the Board of Directors (the ”Board”) of Meda AB (publ) (”Meda”) (STO:MEDAA) pursuant to the Securities Markets Act and//or the Financial Instruments Trading Act. The Board hereby ...
1 2 3

Press Releases

sort by: Date | Relevance
Listing of bond loan(s) issued by Meda AB (publ... [Published GlobeNewswire: Acquisitions News - May 21 2014]
Meda AB (publ) AGM bulletin [Published GlobeNewswire: Advertising News - May 07 2014]
Statement by the Board of Directors of Meda in ... [Published GlobeNewswire: Acquisitions News - Apr 28 2014]
Meda and Valeant terminates joint ventures [Published GlobeNewswire: Advertising News - Apr 07 2014]
Statement by the Board of Directors of Meda [Published GlobeNewswire: Acquisitions News - Apr 04 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.